What happened
The FDA granted De Novo marketing authorization for the Visby Medical Women’s Sexual Health Test. It combines a single-use collection and testing device with an app that displays results, without requiring a prescription or laboratory shipment.
Why it matters
Moving testing into the home can reduce privacy, travel and appointment barriers. Its public-health value still depends on affordability, correct use, confirmatory care when needed and fast access to treatment after a positive result.
What to watch
Retail price, real-world accuracy, linkage to treatment, partner notification, equitable access and evidence on whether home testing reduces untreated infection.
